{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:27:14Z","timestamp":1790659634278,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T00:00:00Z","timestamp":1740268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Asthma prevalence is increasing in the Asia\u2013Pacific region. China and India account for &gt;\u200935% of the world's population and are often underrepresented in clinical studies. This phase 3 study (NCT03782532) evaluated efficacy and safety of dupilumab, a monoclonal antibody blocking interleukin\u20104\/13 signalling, in patients with persistent asthma from China and India.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients (\u2265\u200912\u2009years) were randomised 1:1 to dupilumab 200\u2009mg or matched placebo every 2\u2009weeks for 24\u2009weeks (primary analysis population: blood eosinophils \u2265\u2009150 cells\/\u03bcL or fractional exhaled nitric oxide \u2265\u200925 parts per billion without maintenance oral corticosteroid [OCS]; OCS maintenance population: 300\u2009mg OCS). Primary endpoint: change from baseline to week 12 in forced expiratory volume in 1\u2009s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ). Secondary endpoints: change from baseline to week 24 in 5\u2010item Asthma Control Questionnaire (ACQ\u20105\/7) scores, annualised severe exacerbation rate, and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the primary analysis population (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009414), change in FEV\n                      <jats:sub>1<\/jats:sub>\n                      by week 12 was significantly greater for dupilumab versus placebo (least squares mean difference: 0.31\u2009L [95% CI: 0.23\u20130.39];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). At week 24, greater reductions in ACQ\u20105 score were seen for dupilumab versus placebo (least squares mean difference: \u22120.20 [95% CI: \u22120.35 to \u22120.05];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0097). Dupilumab reduced severe exacerbation risk by 62% versus placebo during the treatment period (relative risk: 0.38 [95% CI: 0.21\u20130.70]; nominal\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). Safety was similar between treatment arms; injection\u2010site reactions were more common with dupilumab treatment (5.0%) than with placebo (1.2%). The OCS maintenance population showed similar outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dupilumab significantly improved lung function and asthma control, numerically reduced asthma exacerbations, and was well tolerated in patients from China and India with persistent asthma and evidence of either type 2 inflammation or OCS maintenance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/\">ClinicalTrials.gov<\/jats:ext-link>\n                      identifier: NCT03782532\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/cea.70005","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T02:35:00Z","timestamp":1741746900000},"page":"691-700","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia\u2013Pacific Region"],"prefix":"10.1111","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2433-2849","authenticated-orcid":false,"given":"Qingling","family":"Zhang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanshan","family":"Zhong","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahajal","family":"Dhooria","sequence":"additional","affiliation":[{"name":"Postgraduate Institute of Medical Education and Research  Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Fu","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Inner Mongolia Medical University  Hohhot China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohui","family":"Fang","sequence":"additional","affiliation":[{"name":"Anhui Chest Hospital  Hefei China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lin","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Wenzhou Medical University  Wenzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Xuzhou Medical University  Xuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Laws","sequence":"additional","affiliation":[{"name":"Sanofi  Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Sanofi  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Li","sequence":"additional","affiliation":[{"name":"Sanofi  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih\u2010Chi","family":"Hu","sequence":"additional","affiliation":[{"name":"Sanofi  Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Maloney","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc.  Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raolat M.","family":"Abdulai","sequence":"additional","affiliation":[{"name":"Sanofi  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lacey B.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Sanofi  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,23]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Global Initiative for Asthma \u201cGINA Report Global Strategy for Asthma Management and Prevention \u201d (2023) https:\/\/ginasthma.org\/wp\u2010content\/uploads\/2023\/07\/GINA\u20102023\u2010Full\u2010report\u201023_07_06\u2010WMS.pdf."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30925-9"},{"key":"e_1_2_11_4_1","unstructured":"Global Asthma Network \u201cThe Global Asthma Report 2022 \u201d (2022) http:\/\/globalasthmareport.org\/resources\/Global_Asthma_Report_2022.pdf."},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2014.4.2.75"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31147-X"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2018.02.010"},{"key":"e_1_2_11_8_1","unstructured":"Government of India \u201cNational Family Health Survey NFHS 5 2019\u20132021 \u201d (2022) https:\/\/ruralindiaonline.org\/en\/library\/resource\/national\u2010family\u2010health\u2010survey\u2010nfhs\u20105\u20102019\u201021\u2010india\/."},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00528-2021"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.4103\/lungindia.lungindia_582_21"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.042"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S391970"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00576-2021"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1323896111"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1324022111"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4624"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14151"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30307-5"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00322-2"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2022.07.008"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106567"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00303-X"},{"key":"e_1_2_11_26_1","unstructured":"European Medicines Agency \u201cDupixent \u201d accessed October 17 2024 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dupixent."},{"key":"e_1_2_11_27_1","unstructured":"Japan Pharmaceuticals and Medical Devices Agency (PMDA) \u201cDupilumab Japan PMDA \u201d (2022) https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/4490405."},{"key":"e_1_2_11_28_1","unstructured":"Z.Wenting \u201cDupixent Receives Green Light to Treat Asthma From Chinese National Medical Products Administration \u201d China Daily (2023) https:\/\/www.chinadaily.com.cn\/a\/202311\/20\/WS655b1d64a31090682a5ef20a.html."},{"key":"e_1_2_11_29_1","unstructured":"United Nations Population Fund \u201cWorld Population Dashboard \u201d accessed October 17 2024 https:\/\/www.unfpa.org\/data\/world\u2010population\/IN."},{"key":"e_1_2_11_30_1","unstructured":"Global Initiative for Asthma \u201cGlobal Strategy for Asthma Management and Prevention 2017 \u201d (2017) https:\/\/ginasthma.org\/wp\u2010content\/uploads\/2019\/01\/2017\u2010GINA.pdf."},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.04.002"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2022.14.2.182"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00204-2019"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14611"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.06.036"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2023.2185895"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.05.019"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02479-0"},{"key":"e_1_2_11_39_1","first-page":"261","article-title":"A Retrospective Study of Changes of Histopathology of Nasal Polyps in Adult Chinese in Central China","volume":"57","author":"Jiang W. X.","year":"2019","journal-title":"Rhinology"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100531"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.710"},{"key":"e_1_2_11_42_1","unstructured":"WHO \u201cNumber of Clinical Trial Registrations by Location Disease Phase of Development Age and Sex of Trial Participants (1999\u20132022) \u201d (2023) https:\/\/www.who.int\/observatories\/global\u2010observatory\u2010on\u2010health\u2010research\u2010and\u2010development\/monitoring\/number\u2010of\u2010trial\u2010registrations\u2010by\u2010year\u2010location\u2010disease\u2010and\u2010phase\u2010of\u2010development."},{"key":"e_1_2_11_43_1","unstructured":"Clinical Trials Arena \u201cThe Great Wall: Why Overseas Sponsors Are Yet to Fully Tap Into China's Clinical Trial Resources \u201d (2022) https:\/\/www.clinicaltrialsarena.com\/features\/china\u2010clinical\u2010trial\u2010challenges\u2010cta\u2010exclusive\/?cf\u2010view."}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cea.70005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T09:58:02Z","timestamp":1764151082000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cea.70005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,23]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1111\/cea.70005"],"URL":"https:\/\/doi.org\/10.1111\/cea.70005","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,23]]},"assertion":[{"value":"2024-08-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}